The Senores Pharmaceuticals IPO is structured as a book-built issue. It consists of a fresh issue amounting to Rs 50.00 crore and an offer for sale of 0.21 crore shares.
The subscription for the Senores Pharmaceuticals IPO is scheduled to open on December 20, 2024, and will close on December 24, 2024. The allotment of shares is expected to be finalized on Thursday, December 26, 2024. The IPO is planned to be listed on BSE and NSE, with the tentative listing date set for Monday, December 30, 2024.
The price bands for the Senores Pharmaceuticals IPO have not yet been announced.
Get the Senores Pharmaceuticals IPO RHP for detailed information.
| IPO Date | December 20, 2024 to December 24, 2024 |
| Listing Date | December 30, 2024 |
| Face Value | ₹ 10 / Share |
| Price Band | ₹ 372 to ₹ 391 / Share |
| Lot Size | 38 Shares |
| Total Issue Size | ₹582.11 Cr |
| Fresh Issue | ₹ 500.00Cr |
| Offer for Sale | 21,00,000 |
| Employee Discount | |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 3,32,65,865 |
| Share holding post issue | 4,60,53,588 |
| Market Maker portion |
Senores Pharmaceuticals Limited IPO opens on December 20, 2024, and closes on December 24, 2024.
| IPO Open Date | December 20, 2024 |
| IPO Close Date | December 24, 2024 |
| Basis of Allotment | December 26, 2024 |
| Initiation of Refunds | December 27, 2024 |
| Credit of Shares to Demat | December 27, 2024 |
| Listing Date | December 30, 2024 |
| Cut-off time for UPI mandate confirmation | December 24, 2024 |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | Rs.14,858 |
| Retail (Max) | 13 | 494 | Rs.193,154 |
| S-HNI (Min) | 14 | 532 | Rs.208,012 |
| S-HNI (Max) | 67 | 2,546 | Rs.995,486 |
| B-HNI (Min) | 68 | 2,584 | Rs.1,010,344 |
| HNI (Min) |
| Share Holding Pre Issue | 71.10% |
| Share Holding Post Issue |
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | |
|
| Market Maker Shares Offered | |
|
| Other Shares Offered | |
|
| QIB Shares Offered | Not less than 75% of the Net Issue |
|
| NII (HNI) Shares Offered | Not more than 15% of the Net Isssue |
|
| bNII > ₹10L | |
|
| sNII < ₹10L | |
|
| Retail Shares Offered | Not more than 10% of the Net Issue |
|
| Employee Shares Offered | |
|
| Total Shares Offered | |
| Bid Date | 2024-12-19 |
| Shares Offered | |
| Anchor Portion Size (In Cr.) | 260.63 |
| Anchor lock-in period end date for 50% shares (30 Days) | January 25, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | March 26, 2025 |
Incorporated in December 2017, Senores Pharmaceuticals Limited is engaged in the development and manufacturing of a range of pharmaceutical products, primarily targeting the regulated markets of the US, Canada, and the UK, while also catering to emerging markets.
The company's product portfolio includes Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets, Topiramate Capsules, and Ivermectin Tablets for regulated markets.
As of September 30, 2024, 55 products have been launched by the company in key therapeutic areas, including antibiotics and anti-fungal treatments. Partnerships have been established with distributors and hospitals across several states in India.
The company operates three dedicated R&D facilities in India and the US as of September 30, 2024.
Operations have expanded into emerging markets across 43 countries, with critical care injectables and APIs being manufactured.
The company's manufacturing unit is located in Ahmedabad, Gujarat.
| KPI | Values |
|---|---|
| ROE | 23.60% |
| ROCE | 11.73% |
| Debt/Equity | 1.07 |
| RoNW | 23.60% |
| P/BV | |
| PAT Margin (%) | 15.25 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 9.83 | 13.86 |
| P/E (x) | 39.77 | 28.21 |
The Net Proceeds are proposed to be utilized by the Company for the following objectives:
Senores Pharmaceuticals Limited 1101 to 1103, 11th floor, South Tower, ONE 42 oppositeJayantilal Park, Ambali Bopal Road, Ahmedabad,-380054 Phone: +91-79-29999857 Email: cs@senorespharma.com Website: https://senorespharma.com/ |
Link Intime India Private Ltd Phone: +91-22-4918 6270 Email: senorespharma.ipo@linkintime.co.in Website: https://linkintime.co.in/Initial_Offer/public-issues.html |
Lamfindia specializes in offering innovative financial solutions, including stock broker services, mutual fund investments, and IPO guidance.